Quest Diagnostics Incorporated reported a notable increase in financial performance for the first quarter of 2026, with net revenues reaching $2.895 billion, a 9.2% rise from $2.652 billion in the same period of 2025. The company's operating income also improved, rising to $399 million from $346 million, marking a 15.5% increase. Net income attributable to Quest Diagnostics was $252 million, up from $220 million, while diluted earnings per share increased to $2.24 from $1.94, reflecting a 15.5% growth.
The growth in revenue was primarily driven by a 9.4% increase in the Diagnostic Information Services (DIS) segment, which accounted for the majority of the company's revenue. The volume of test requisitions rose by 10.9%, with organic growth contributing 10.8%. This increase was partially attributed to new partnerships, including a collaboration with Corewell Health, which enhanced laboratory testing services. However, revenue per requisition saw a slight decline of 1.3%, influenced by a shift in business mix towards more routine tests.
In terms of operational developments, Quest Diagnostics completed a significant acquisition in January 2026, forming a new entity with Corewell Health to provide laboratory testing in Michigan. This venture is expected to enhance the company's service offerings and operational capabilities in the region. Additionally, the company is implementing its multi-year "Invigorate" program aimed at achieving annual cost savings of 3% through improved productivity and efficiency across various operational areas.
Financially, the company reported cash and cash equivalents of $393 million as of March 31, 2026, a decrease from $420 million at the end of 2025. Net cash provided by operating activities was $278 million, down from $314 million in the previous year, primarily due to timing differences in receipts and disbursements. The company also announced a quarterly cash dividend of $0.86 per share, up from $0.80 in 2025, and authorized an additional $1 billion for share repurchases, with $1.4 billion remaining available under the program.
Looking ahead, Quest Diagnostics remains focused on leveraging its strategic partnerships and operational efficiencies to drive growth. The company anticipates continued revenue growth from its DIS segment, supported by ongoing investments in technology and infrastructure. However, it also acknowledges potential challenges from market conditions and regulatory changes that could impact its operations and financial performance.
About QUEST DIAGNOSTICS INC
Quest Diagnostics is a leading provider of diagnostic testing and information services, serving healthcare providers, hospitals, patients, and payers primarily in the U.S. The company offers routine, advanced, and molecular diagnostics, leveraging extensive data assets, innovative technology, and a broad network of laboratories and patient centers. Its core value lies in delivering high-quality, accessible insights to improve health outcomes and support value-based care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.